Acute Ischemic Stroke: The 4.5-Hour IV Thrombolytic Window, Mechanical Thrombectomy, and Penumbra Salvage
Key Clinical Takeaways
- Acute ischemic stroke accounts for 87% of all cerebrovascular accidents, caused by thromboembolic occlusion of cerebral arteries.
- Intravenous thrombolytic therapy (Alteplase or Tenecteplase) must be initiated within 4.5 hours of documented symptom onset ('last known well').
- Mechanical Thrombectomy (catheter stent retriever) is the standard of care for Large Vessel Occlusions (LVO) of the internal carotid and proximal middle cerebral artery.
- Under DAWN and DEFUSE-3 clinical trial criteria, mechanical thrombectomy can be performed up to 24 hours post-onset when perfusion CT demonstrates salvageable ischemic penumbra.
- Permissive hypertension (allowing BP up to 220/120 mmHg in non-thrombolyzed patients, or <185/110 mmHg prior to thrombolysis) preserves collateral penumbral perfusion.
Emergency Clinical Warning
Stroke is an extreme emergency: 'Time is Brain'—1.9 million neurons die every minute an ischemic stroke is untreated. Call 911 immediately if you observe facial droop, arm weakness, or slurred speech.
Pathophysiology of the Ischemic Core and Penumbra
Acute Ischemic Stroke (AIS) occurs when a thrombus or embolus acutely occludes a major intracranial or extracranial cerebral artery, terminating blood flow to downstream brain parenchyma. Within seconds of localized blood flow falling below 10 to 12 mL/100g/min, neuronal energy stores are exhausted, cellular ATP synthesis halts, and membrane sodium-potassium ATPase pumps fail, precipitating massive intracellular calcium influx, cytotoxic edema, and rapid cell necrosis—forming the irreversible 'Ischemic Core'.
Surrounding this necrotic core lies the 'Ischemic Penumbra'—a rim of functionally impaired but structurally viable, salvageable brain tissue maintained by collateral blood flow via the circle of Willis and leptomeningeal anastomoses. If collateral perfusion is exhausted without prompt arterial recanalization, the penumbra progressively converts into irreversible infarct core. In untreated large-vessel ischemic stroke, an estimated 1.9 million neurons, 14 billion synapses, and 7.5 miles of myelinated axonal fibers are destroyed every single minute, establishing the clinical adage: *'Time is Brain.'*
Emergency Pre-Hospital Triage and NIHSS Assessment
Rapid recognition and hospital pre-notification by Emergency Medical Services (EMS) are vital. The validated BE-FAST mnemonic ensures rapid community screening: - Balance: Sudden loss of balance or coordination (ataxia). - Eyes: Sudden loss of vision, diplopia, or visual field cut. - Face: Unilateral facial droop or asymmetrical smile. - Arm: Unilateral arm weakness or drift when held elevated. - Speech: Slurred speech, expressive aphasia, or receptive word confusion. - Time: Critical imperative to call 911 immediately and ascertain the exact 'Last Known Well' (LKW) time.
Upon arrival at a designated Comprehensive or Thrombectomy-Capable Stroke Center, an emergency stroke code is activated. The emergency neurological team conducts an immediate National Institutes of Health Stroke Scale (NIHSS) score—a validated 15-item quantitative neurological exam ranging from 0 (normal) to 42 (severe stroke)—evaluating consciousness, vision, gaze palsy, motor strength, sensory loss, ataxia, language, and neglect.
Intravenous Thrombolysis: Alteplase and the Rise of Tenecteplase
Emergency non-contrast head computed tomography (NCCT) must be acquired within 20 minutes of hospital arrival to immediately exclude intracranial hemorrhage. If hemorrhage is ruled out, eligible patients presenting within 4.5 hours of their documented Last Known Well qualify for intravenous thrombolysis: - Recombinant Tissue Plasminogen Activator (Alteplase / tPA): Binds to fibrin in a thrombus and converts trapped plasminogen to active plasmin, enzymatic digesting the fibrin clot matrix. Standard dose is 0.9 mg/kg (max 90 mg; 10% administered as an IV bolus over 1 minute, followed by 90% infused over 60 minutes). - Tenecteplase (TNKase): A bioengineered variant of tPA with greater fibrin specificity and an 80-fold longer half-life. Tenecteplase is administered as a single, rapid intravenous bolus over 5 seconds (0.25 mg/kg; max 25 mg), eliminating the cumbersome 1-hour IV infusion pump. Major Phase III clinical trials (AcT and EXTEND-IA TNK) proved tenecteplase is non-inferior or superior to alteplase, particularly for promoting early recanalization of large vessel occlusions prior to thrombectomy.
Blood pressure must be strictly lowered below 185/110 mmHg using intravenous labetalol or nicardipine prior to thrombolytic infusion, and maintained below 180/105 mmHg for 24 hours post-thrombolysis to avert symptomatic intracranial hemorrhage.
Endovascular Mechanical Thrombectomy: The 24-Hour Window
While intravenous thrombolytics are effective for smaller distal vessels, they achieve recanalization in fewer than 30% of Large Vessel Occlusions (LVO)—specifically occlusions of the internal carotid artery (ICA) terminus, the M1 or proximal M2 segment of the middle cerebral artery (MCA), or the basilar artery.
Endovascular Mechanical Thrombectomy (EVT) represents one of the most miraculous breakthroughs in modern emergency medicine. Performed under fluoroscopic guidance by an interventional neurosurgeon or neurointerventionalist, a microcatheter is advanced from the femoral or radial artery into the intracranial vasculature. A specialized stent-retriever (e.g., Solitaire, Trevo) or direct contact aspiration catheter traps and physically extracts the occlusive clot from the cerebral vessel, restoring immediate reperfusion (TICI 2b/3 flow).
The landmark DAWN and DEFUSE-3 clinical trials proved that mechanical thrombectomy can be successfully performed up to 24 hours from last known well in selected patients. Using advanced perfusion neuroimaging (CT Perfusion [CTP] or diffusion-weighted MRI), automated software (RAPID) calculates the precise volume ratio between the irreversible ischemic core (cerebral blood flow <30%) and the salvageable penumbra (Tmax >6 seconds). Patients with a small core and a large clinical mismatch salvageable penumbra achieve dramatic functional recovery and independence.
Acute Ischemic Stroke Interventions: Emergency Eligibility and Time Windows
| Intervention Modality | Eligible Time Window | Target Anatomy / Indication | Key Clinical Contraindications | Primary Clinical Endpoint |
|---|---|---|---|---|
| IV Alteplase (tPA) | 0 to 4.5 hours from LKW | All acute ischemic strokes without bleed | Active bleed, BP >185/110, recent major surgery, DOAC use | Early enzymatic enzymatic thrombus dissolution |
| IV Tenecteplase (TNK) | 0 to 4.5 hours from LKW | All acute ischemic strokes; preferred in LVO | Identical to alteplase contraindications | Single 5-second bolus; superior recanalization |
| Mechanical Thrombectomy | 0 to 6 hours (Standard window) | Large Vessel Occlusion (ICA, M1 MCA, Basilar) | Massive established core infarction (ASPECTS <3-5) | Direct physical stent-retriever clot extraction |
| Extended Thrombectomy (DAWN) | 6 to 24 hours (Advanced imaging) | LVO with documented salvageable penumbra on CTP | Large established core (>70 mL), absence of penumbra | Preservation of functional independence (mRS 0-2) |
Frequently Asked Clinical Questions
Peer-Reviewed Clinical References & Guidelines
- Powers WJ, Rabinstein AA, Ackerson T, et al. Guidelines for the Early Management of Patients With Acute Ischemic Stroke: 2019 Update. Stroke. 2019;50(12):e344-e418.
- Nogueira RG, Jadhav AP, Haussen DC, et al. Thrombectomy 6 to 24 Hours after Stroke with a Mismatch between Deficit and Infarct (DAWN Trial). N Engl J Med. 2018;378(1):11-21.
- Campbell BCV, Mitchell PJ, Churilov L, et al. Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke (EXTEND-IA TNK). N Engl J Med. 2018;378(17):1573-1582.